



SDI Review Form 1.6

Journal Name:	Journal of Cancer and Tumor International
Manuscript Number:	2015_JCTI_18131
Title of the Manuscript:	MiRNA and target oncogenes in Triple negative breast cancer; major players in age and ethnic related neoplastic events
Type of the Article	Review Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	1 - Title: The second part of the title (i.e. "major players in age and ethnic related neoplastic events") should be deleted or changed (particularly the expression "major players"). 2- Abstract: The Abstract should not contain any acronyms (e.g. TNBC). 3 - Abstract: The Abstract should be shortened. 4- Introduction: This section should be divided into three paragraphs, starting from lines 34, 44 (A study carried out by...) and 52 ("MicroRNAs..."). 5- Characteristic features of TNBC: This section should be divided into four paragraphs, starting from lines 65, 68, 76, 84 and 92 (from i, ii, iii and iv respectively) 6- Bio-genesis of microRNAs: In this section, in many instances, words have been written without a space in between. Hence, a space is needed in these cases. 7- MicroRNA and Epithelial-to-Mesenchymal Transition (EMT); players in TNBC and metastases: The second part of this subtitle (i.e. "players in TNBC and metastases") should be deleted 8 - Line 120: "Tumorigenesis and progression" should be changed to "Tumorigenesis and tumor progression" (i.e. the word "tumor" should be added). 9- Line 162: Since "ErbB2" refers to humans, it should be changed to "ERBB2"	Author wish to thank the reviewer for his/her suggestions/corrections. 1. Done. Lines: 2-4 "MiRNA and target oncogenes regulation in Triple negative breast cancer; an age and ethnic related neoplastic events". 2. Noted. Abstract edited according to reviewer's suggestion. 3. Done. Lines 11-13 and 22-24 deleted. Abstract shortened from 303 words to 235 words. 4. Edited. Lines 40 and 50 5. Done. Line 61, 65, 73, 81, 89 6. Edited. 7. Done. Line 115. 8. Done. Line 116. 9. Edited. Line 158



SDI Review Form 1.6

<u>Minor</u> REVISION comments	1- Introduction, line 36: “cancerrelated” should be changed to “cancer-related”. 2- Introduction, line 61: “The review article...” should be changed to “This review article...”. 3- Line 126: “Epigenetic” should be changed to “Epigenetics” 4- Line 131: “target” should be changed to “targets”. 5- Line 166: “PARP inhibitors treatments” should be changed to either “PARP inhibitor treatments” or “treatments with PARP inhibitors”. 6- Line 171: “compare” should be changed to “compared” 7- Line 180: “microRNA” should be changed to “microRNAs”. 8- Line 180: “in wide variety” should be changed to “in a wide variety” 9- Line 186: “(moreover” should be changed to “. Moreover”. 10- Prognostic and Therapeutic markers in TBNC: In this section, in many instances, words have been written without a space in between. Hence, a space is needed in these cases (e.g. in line 218 “triplegenegative ” should be changed to “triple negative”; in line 222 “epithelialtomesenchymal” should be changed to “epithelial to mesenchymal”. 11- Line 269: “recent” should be changed to “Recent”.	1 Done. Line 31. 2 Done. Line 57 3 Done. Line 123. 4 Done. Line 127. 5 Edited. Line 162. 6 Done. Line 167 7 Done. Line 185 8 Done. Line 185 9 Done. Line 182 10 Done. 11 Done. Line 165
<u>Optional/General</u> comments		